Alnylam Pharmaceuticals (NASDAQ:ALNY) Sets New 52-Week Low – What’s Next?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)’s share price reached a new 52-week low on Friday . The stock traded as low as $281.77 and last traded at $287.1620, with a volume of 170604 shares. The stock had previously closed at $289.39.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Citigroup assumed coverage on shares of Alnylam Pharmaceuticals in a research note on Tuesday, May 19th. They set a “buy” rating and a $380.00 price objective on the stock. Freedom Capital upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, February 17th. Royal Bank Of Canada reduced their target price on shares of Alnylam Pharmaceuticals from $450.00 to $445.00 and set an “outperform” rating for the company in a report on Friday, May 1st. Finally, Wall Street Zen raised shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $463.13.

Alnylam Pharmaceuticals Stock Down 2.3%

The company has a debt-to-equity ratio of 0.94, a quick ratio of 3.06 and a current ratio of 3.13. The stock has a market cap of $37.76 billion, a P/E ratio of 77.28 and a beta of 0.29. The stock’s fifty day simple moving average is $304.31 and its 200-day simple moving average is $343.68.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.87 by $1.12. The firm had revenue of $1.17 billion during the quarter, compared to the consensus estimate of $1.12 billion. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The business’s revenue for the quarter was up 96.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.44) EPS. As a group, research analysts forecast that Alnylam Pharmaceuticals, Inc. will post 7.47 earnings per share for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, insider Melissa Mclaughlin sold 2,286 shares of the business’s stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $330.42, for a total value of $755,340.12. Following the completion of the sale, the insider owned 9,443 shares of the company’s stock, valued at $3,120,156.06. The trade was a 19.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director David E. I. Pyott sold 3,830 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the sale, the director directly owned 1,582 shares of the company’s stock, valued at approximately $473,302.76. This trade represents a 70.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 7,740 shares of company stock valued at $2,420,214 in the last three months. Insiders own 0.86% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Parallel Advisors LLC lifted its stake in Alnylam Pharmaceuticals by 7.9% in the 1st quarter. Parallel Advisors LLC now owns 891 shares of the biopharmaceutical company’s stock valued at $295,000 after purchasing an additional 65 shares during the last quarter. Glenmede Trust Co. NA lifted its stake in Alnylam Pharmaceuticals by 8.3% in the 1st quarter. Glenmede Trust Co. NA now owns 731 shares of the biopharmaceutical company’s stock valued at $242,000 after purchasing an additional 56 shares during the last quarter. Groupama Asset Managment lifted its stake in Alnylam Pharmaceuticals by 2.5% in the 1st quarter. Groupama Asset Managment now owns 36,767 shares of the biopharmaceutical company’s stock valued at $12,165,000 after purchasing an additional 889 shares during the last quarter. Segall Bryant & Hamill LLC bought a new position in Alnylam Pharmaceuticals in the 1st quarter valued at approximately $641,000. Finally, Janus Henderson Group PLC lifted its stake in Alnylam Pharmaceuticals by 7.8% in the 1st quarter. Janus Henderson Group PLC now owns 147,089 shares of the biopharmaceutical company’s stock valued at $48,661,000 after purchasing an additional 10,664 shares during the last quarter. Institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.